CMEOF (Creo Medical Group) Cyclically Adjusted Revenue per Share: $0.16 (As of Dec. 2025)


CMEOF Creo Medical Group PLC CMEOF
52 GF Score
Price $0.20
GF Value $0.24
! 6 Warning Signs
View Full Analysis

What is Creo Medical Group Cyclically Adjusted Revenue per Share?

Creo Medical Group CMEOF 52 Cyclically Adjusted Revenue per Share is $0.16 as of Dec. 2025. GuruFocus rates CMEOF with a GF Score™ of 52/100 and a GF Value™ of $0.24. The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Creo Medical Group's adjusted revenue per share data for the fiscal year that ended in Dec. 2025 was $0.019. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.16 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Creo Medical Group's average Cyclically Adjusted Revenue Growth Rate was -11.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-09), Creo Medical Group's current stock price is $ 0.20. Creo Medical Group's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec. 2025 was $0.16. Creo Medical Group's Cyclically Adjusted PS Ratio of today is 1.25.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of Creo Medical Group was 2.22. The lowest was 1.08. And the median was 1.47.


Creo Medical Group  (OTCPK:CMEOF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Creo Medical Group's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.20/0.16
=1.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of Creo Medical Group was 2.22. The lowest was 1.08. And the median was 1.47.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Creo Medical Group Cyclically Adjusted Revenue per Share Related Terms


Creo Medical Group Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Creo Medical Group's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Creo Medical Group Cyclically Adjusted Revenue per Share Chart

Creo Medical Group Annual Data
Trend Feb15 Feb16 Jun17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.16

Creo Medical Group Semi-Annual Data
Feb15 Feb16 Dec16 Jun17 Dec17 Jun18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.16

CMEOF vs ABT, SYK, MDT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Creo Medical Group's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Creo Medical Group Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Creo Medical Group's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Creo Medical Group's Cyclically Adjusted PS Ratio falls into.


CMEOF
52GF Score
Creo Medical Group PLC CMEOF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Creo Medical Group Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Creo Medical Group's adjusted Revenue per Share data for the fiscal year that ended in Dec. 2025 was:

Adj_RevenuePerShare=Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=0.019/139.9000*139.9000
=0.019

Current CPI (Dec. 2025) = 139.9000.

Creo Medical Group Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201502 0.000 99.500 0.000
201602 0.000 100.100 0.000
201706 0.000 103.500 0.000
201912 0.000 108.500 0.000
202012 0.079 109.400 0.101
202112 0.196 114.700 0.239
202212 0.176 125.300 0.197
202312 0.016 130.500 0.017
202412 0.014 135.100 0.014
202512 0.019 139.900 0.019

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.16 mean?
Creo Medical Group (CMEOF) has a Cyclically Adjusted Revenue per Share of $0.16 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Creo Medical Group and its competitors.
Is Creo Medical Group's Cyclically Adjusted Revenue per Share too high?
Creo Medical Group's current Cyclically Adjusted Revenue per Share is $0.16. Overall, Creo Medical Group has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Creo Medical Group's Cyclically Adjusted Revenue per Share compare to ABT and SYK?
Creo Medical Group's Cyclically Adjusted Revenue per Share of $0.16 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Creo Medical Group and its competitors. Creo Medical Group's current Cyclically Adjusted Revenue per Share is $0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creo Medical Group stock overvalued right now?
Creo Medical Group (CMEOF) has a current Cyclically Adjusted Revenue per Share of $0.16. The stock's GF Value™ is $0.24, compared to a current price of $0.20 — trading 16.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $0.16. Creo Medical Group's overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Creo Medical Group (CMEOF), the current Cyclically Adjusted Revenue per Share is $0.16 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Creo Medical Group (CMEOF) Overvalued in 2026?

Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued. The current stock price of $0.20 is trading 16.7% below its estimated GF Value™ of $0.24.

Key valuation signals for CMEOF:

  • Cyclically Adjusted Revenue per Share: $0.16
  • GF Value™: $0.24 vs. price of $0.20 (16.7% below fair value)
  • GF Score™: 52/100 with 6 warning signs

No single metric tells the full story. See the CMEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Creo Medical Group Business Description

Other Exchanges CREO:UK
Address Beaufort Park Way, Unit 2, Creo House, Beaufort Park, Chepstow, GBR, NP16 5UH
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
52GF Score

Get the complete analysis for CMEOF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.20
Price
$0.24
GF Value